Lecture

Understanding Cancer Therapies

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

In course

BIO-471: Cancer biology I

The course covers in detail molecular mechanisms of cancer development with emphasis on cell cycle control, genome stability, oncogenes, tumor suppressor genes, signaling pathways involved in cancer, genomic cancer analysis and rational cancer therapies. ...

Description

This lecture covers the different types of cancer therapies, including surgery, chemotherapies, and radiotherapies. It delves into the mechanisms of action of chemotherapeutic agents, such as microtubule inhibitors and topoisomerase inhibitors. The lecture also discusses the limitations of chemotherapy, the concept of resistance, and the development of targeted therapies to block specific oncogenic proteins altered in cancer.

Instructors (3)

Joachim Lingner

PhD at the Biocenter, University of Basel 1989-1992 (Supervisor: Walter Keller). Postdoc at the Howard Hughes Medical Institute, University of Colorado at Boulder 1993-1997 (Supervisor: Thomas Cech). Junior group leader at ISREC 1997-2001. Senior group leader at ISREC since 2002. Associate Professor at EPFL 2005-2008. Full Professor at EPFL since 2009. Honors: START-fellowship from the Swiss National Science Foundation in 1997; Friedrich Miescher Prize from the Swiss Society of Biochemistry in 2002; EMBO member in 2005; ERC advanced investigator grant in 2008.

Viesturs Simanis

Viesturs Simanis was awarded a degree in Biochemistry from Imperial College London. He carried out his doctoral studies with David Lane at Imperial College, London University, and postdoctoral studies with Paul Nurse (London and Oxford). He has been a group leader at ISREC since 1988. In 2006 he was appointed Associate Professor at the EPFL School of Life Sciences

Elisa Oricchio

Expertise Cancer geneticsMouse modelsTherapyStem cellsLymphoma Teaching & PhD PhD Students Vamsi Krishna Polavarapu, Asli Ece Kasapoglu, Konstantina Georgakopoulou, Eleni Balli Past EPFL PhD Students Maria Christine Donaldson, Elena Battistello, Daniel Pereira Duarte, Frédérica Schyrr, Ruxandra-Andreea Lambuta, Aaron Simone Petruzzella, Jixing Zhong, Justine Epiney Courses Cancer biology I BIO-471 The course covers in detail molecular mechanisms of cancer development with emphasis on cell

Official source

Ontological neighbourhood

Biology

Cell biology: Cell cycle, Cancer

Health sciences

Hematology: Lymphoma

Related concepts (32)

Lymphoma

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night. Many subtypes of lymphomas are known.

Mitosis

In cell biology, mitosis (maɪˈtoʊsɪs) is a part of the cell cycle in which replicated chromosomes are separated into two new nuclei. Cell division by mitosis gives rise to genetically identical cells in which the total number of chromosomes is maintained. Therefore, mitosis is also known as equational division. In general, mitosis is preceded by S phase of interphase (during which DNA replication occurs) and is often followed by telophase and cytokinesis; which divides the cytoplasm, organelles and cell membrane of one cell into two new cells containing roughly equal shares of these cellular components.

Follicular lymphoma

Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as lymphocytes. The cancer originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts. These cells normally occupy the follicles (nodular swirls of various types of lymphocytes) in the germinal centers of lymphoid tissues such as lymph nodes. The cancerous cells in FL typically form follicular or follicle-like structures (see adjacent Figure) in the tissues they invade.

DNA repair

DNA repair is a collection of processes by which a cell identifies and corrects damage to the DNA molecules that encode its genome. In human cells, both normal metabolic activities and environmental factors such as radiation can cause DNA damage, resulting in tens of thousands of individual molecular lesions per cell per day. Many of these lesions cause structural damage to the DNA molecule and can alter or eliminate the cell's ability to transcribe the gene that the affected DNA encodes.

Hodgkin lymphoma

Hodgkin lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes, where multinucleated Reed–Sternberg cells (RS cells) are present in the patient's lymph nodes. The condition was named after the English physician Thomas Hodgkin, who first described it in 1832. Symptoms may include fever, night sweats, and weight loss. Often, nonpainful enlarged lymph nodes occur in the neck, under the arm, or in the groin. Those affected may feel tired or be itchy.

Related lectures (64)

Cancer Biology: Base Excision Repair

Covers cancer biology topics on base excision repair, cellular responses to DNA damage, p53 regulation, and apoptosis mechanisms.

B-Cell Receptor Signaling in Lymphoma and Leukemia

Explores B-cell receptor signaling in lymphoma and leukemia, drug resistance mechanisms, CRISPR/Cas9 gene editing, mTOR inhibitors, cell cycle inhibition, and undruggable oncogenes.

Introduction: small molecule drugs for cancer

Introduces small molecule drugs for cancer treatment, covering drug discovery, mechanisms of action, and historical development of anti-cancer agents.

Immune Cell Engineering: Targeting Checkpoint Inhibitors

Explores immune cell engineering for cancer therapy, emphasizing checkpoint inhibitor targeting through innovative delivery methods.

Lymphadenitis and Lymphoma: Clinical Correlations